company background image
ACIU

AC Immune NasdaqGM:ACIU Stock Report

Last Price

US$2.62

Market Cap

US$202.4m

7D

-3.0%

1Y

-48.9%

Updated

29 Nov, 2022

Data

Company Financials +
ACIU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ACIU Stock Overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

AC Immune SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AC Immune
Historical stock prices
Current Share PriceUS$2.62
52 Week HighUS$5.40
52 Week LowUS$2.06
Beta0.53
1 Month Change-9.50%
3 Month Change-13.25%
1 Year Change-48.93%
3 Year Change-66.92%
5 Year Change-78.02%
Change since IPO-83.27%

Recent News & Updates

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Recent updates

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Shareholder Returns

ACIUUS BiotechsUS Market
7D-3.0%-1.0%-0.9%
1Y-48.9%-15.2%-18.9%

Return vs Industry: ACIU underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: ACIU underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is ACIU's price volatile compared to industry and market?
ACIU volatility
ACIU Average Weekly Movement12.8%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ACIU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ACIU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003137Andrea Pfeiferhttps://www.acimmune.com

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer’s disease (AD).

AC Immune SA Fundamentals Summary

How do AC Immune's earnings and revenue compare to its market cap?
ACIU fundamental statistics
Market CapUS$202.41m
Earnings (TTM)-US$76.98m
Revenue (TTM)US$4.13m

49.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACIU income statement (TTM)
RevenueCHF3.93m
Cost of RevenueCHF65.32m
Gross Profit-CHF61.39m
Other ExpensesCHF11.89m
Earnings-CHF73.28m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin-1,560.50%
Net Profit Margin-1,862.74%
Debt/Equity Ratio0%

How did ACIU perform over the long term?

See historical performance and comparison